TDMS Study 05044-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
4-VINYL-1-CYCLOHEXENE DIEPOXIDE
NTP Experiment-Test: 05044-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
Facility: Battelle Columbus Laboratory
Chemical CAS #: 106-87-6
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund 3 3 8 29
Dead 3 7 7 9
Accident 1
Drowned 1 1
Survivors
Terminal Sacrifice 30 31 14 10
Moribund 7 7 15 2
Dead 4 1 6
Accidently Killed 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (48) (49) (48) (49)
Sarcoma, Metastatic 1 (2%)
Intestine Large, Cecum (50) (48) (49) (50)
Intestine Large, Colon (50) (50) (50) (50)
Sarcoma, Metastatic 1 (2%)
Intestine Large, Rectum (50) (49) (50) (50)
Intestine Small, Ileum (48) (50) (50) (50)
Intestine Small, Jejunum (50) (50) (50) (50)
Liver (50) (50) (50) (50)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 2 (4%) 3 (6%) 3 (6%) 2 (4%)
Hepatocellular Carcinoma, Multiple,
Metastatic 1 (2%)
Hepatocellular Adenoma 7 (14%) 6 (12%) 5 (10%) 2 (4%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%)
Histiocytic Sarcoma, Metastatic, Metastatic,
Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic 2 (4%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Mesentery (5) (4) (2)
Hemangioma 1 (20%)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (25%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (20%)
Page 2
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic 1 (50%)
Pancreas (50) (49) (50) (50)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Salivary Glands (50) (49) (50) (50)
Stomach, Forestomach (49) (50) (50) (50)
Squamous Cell Papilloma 3 (6%) 1 (2%) 3 (6%)
Stomach, Glandular (50) (49) (50) (50)
Adenoma 1 (2%)
Tooth (1) (1)
Peridontal Tissue, Histiocytic Sarcoma,
Metastatic 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (50) (50) (50)
Bilateral, Capsule, Adenoma 1 (2%)
Capsule, Adenoma 2 (4%) 1 (2%) 6 (12%) 3 (6%)
Capsule, Carcinoma 1 (2%)
Extra Adrenal Tissue, Histiocytic Sarcoma,
Metastatic 1 (2%) 1 (2%)
Adrenal Gland, Cortex (50) (50) (50) (49)
Squamous Cell Carcinoma, Metastatic 1 (2%)
Adrenal Gland, Medulla (50) (49) (50) (48)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (49) (50) (49) (50)
Adenoma 1 (2%)
Pituitary Gland (49) (48) (47) (45)
Pars Distalis, Adenoma 17 (35%) 16 (33%) 5 (11%)
Pars Distalis, Carcinoma 1 (2%)
Pars Distalis, Granular Cell Tumor Malignant,
Metastatic 1 (2%)
Pars Intermedia, Adenoma 2 (4%) 1 (2%)
Thyroid Gland (49) (49) (50) (50)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Osteosarcoma, Metastatic, Metastatic 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (49) (50)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Malignant 2 (4%) 2 (4%)
Granulosa Cell Tumor Benign 5 (10%) 10 (20%)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%) 1 (2%)
Luteoma 1 (2%)
Mixed Tumor Benign 9 (18%) 6 (12%)
Bilateral, Histiocytic Sarcoma, Metastatic 1 (2%)
Bilateral, Mixed Tumor Benign 2 (4%)
Uterus (50) (49) (49) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangioma 1 (2%)
Mast Cell Tumor NOS 1 (2%)
Femoral, Hemangiosarcoma 1 (2%)
Lymph Node (49) (49) (47) (50)
Squamous Cell Carcinoma, Metastatic 1 (2%) 2 (4%)
Squamous Cell Carcinoma, Metastatic,
Metastatic 1 (2%)
Axillary, Adenocarcinoma, Metastatic,
Mammary Gland 1 (2%)
Axillary, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%) 1 (2%)
Lumbar, Histiocytic Sarcoma, Metastatic 1 (2%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Lymph Node, Mandibular (48) (49) (47) (48)
Histiocytic Sarcoma, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%) 5 (11%) 4 (8%)
Axillary, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Deep Cervical, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Page 4
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lumbar, Squamous Cell Carcinoma, Metastatic,
Skin 1 (2%)
Lymph Node, Mesenteric (6) (4) (6) (7)
Histiocytic Sarcoma, Metastatic 1 (25%)
Spleen (50) (50) (50) (50)
Hemangioma 2 (4%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic 1 (2%)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Capsule, Fibrous Histiocytoma 1 (2%)
Capsule, Histiocytic Sarcoma, Metastatic 1 (2%)
Thymus (42) (45) (33) (33)
Squamous Cell Carcinoma, Metastatic 1 (3%)
Thymoma Benign 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (44) (41) (41) (39)
Adenocarcinoma 1 (2%) 1 (2%) 3 (7%) 4 (10%)
Skin (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Squamous Cell Carcinoma 3 (6%) 2 (4%)
Squamous Cell Carcinoma, Multiple 1 (2%)
Back, Fibrous Histiocytoma 1 (2%)
Back, Osteosarcoma, Metastatic 1 (2%)
Back, Squamous Cell Carcinoma 1 (2%) 3 (6%)
Back, Squamous Cell Carcinoma, Multiple 1 (2%)
Scapula, Basosquamous Tumor Malignant 1 (2%) 1 (2%)
Scapula, Fibrous Histiocytoma 1 (2%)
Scapula, Squamous Cell Carcinoma 5 (10%) 14 (28%) 31 (62%)
Scapula, Squamous Cell Carcinoma, Multiple 1 (2%) 23 (46%) 10 (20%)
Scapula, Squamous Cell Carcinoma, Multiple,
Metastatic 2 (4%)
Scapula, Squamous Cell Carcinoma, Metastatic 2 (4%)
Sebaceous Gland, Adenocarcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Scapula, Squamous Cell
Carcinoma, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (49) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (2) (2)
Back, Sarcoma, Metastatic 1 (50%)
Intercostal, Squamous Cell Carcinoma,
Metastatic, Skin 1 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Adenoma 3 (6%) 5 (10%) 8 (16%) 6 (12%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 4 (8%) 3 (6%) 1 (2%)
Basosquamous Tumor Malignant, Metastatic,
Skin 1 (2%)
Granulosa Cell Tumor Malignant, Metastatic,
Ovary 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic,
Metastatic 1 (2%)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic 2 (4%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%) 9 (18%) 18 (36%)
Bronchiole, Adenocarcinoma, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (43) (46) (42) (45)
Adenoma 5 (12%) 1 (2%) 4 (10%) 8 (18%)
Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma, Metastatic, Metastatic 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Carcinoma, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%) 3 (6%)
Urinary Bladder (49) (49) (48) (50)
Histiocytic Sarcoma, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Leukemia Granulocytic 1 (2%)
Lymphoma Malignant Histiocytic 2 (4%)
Lymphoma Malignant Lymphocytic 4 (8%) 2 (4%) 1 (2%)
Lymphoma Malignant Mixed 10 (20%) 3 (6%) 2 (4%)
Lymphoma Malignant Undifferentiated Cell 4 (8%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 36 47 46
Total Primary Neoplasms 76 59 123 99
Total Animals with Benign Neoplasms 31 25 34 29
Total Benign Neoplasms 52 33 51 42
Total Animals with Malignant Neoplasms 22 22 44 44
Total Malignant Neoplasms 23 26 72 57
Total Animals with Metastatic Neoplasms 3 7 20 29
Total Metastatic Neoplasm 8 19 40 53
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund 3 4 27 30
Dead 6 11 17 20
Drowned 3 2
Survivors
Terminal Sacrifice 38 35 4
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (49) (50) (48) (50)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (50) (50) (46) (50)
Adenoma 1 (2%)
Pheochromocytoma Complex, Diffuse, Metastatic 1 (2%)
Intestine Small, Jejunum (50) (50) (49) (50)
Liver (50) (50) (50) (50)
Basosquamous Tumor Malignant, Metastatic,
Skin 2 (4%)
Hemangioma 1 (2%) 4 (8%)
Hemangioma, Multiple 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%)
Hemangiosarcoma, Multiple 2 (4%)
Hepatocellular Carcinoma 5 (10%) 5 (10%) 4 (8%) 4 (8%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 14 (28%) 6 (12%) 10 (20%) 1 (2%)
Hepatocellular Adenoma, Multiple 4 (8%) 2 (4%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 2 (4%)
Mesentery (1) (1) (1)
Lipoma 1 (100%)
Pancreas (49) (50) (50) (49)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (48) (50)
Carcinoid Tumor Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Tooth (4) (3) (1)
Odontoma 1 (25%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Squamous Cell Carcinoma, Metastatic, Skin 3 (6%) 4 (8%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (50) (49) (50)
Capsule, Adenoma 5 (10%) 5 (10%) 3 (6%) 1 (2%)
Adrenal Gland, Cortex (50) (49) (49) (50)
Medulla, Squamous Cell Carcinoma, Metastatic,
Skin 1 (2%) 1 (2%)
Islets, Pancreatic (48) (50) (47) (48)
Adenoma 1 (2%)
Pituitary Gland (43) (47) (42) (38)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (50) (49) (48)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1) (1) (1)
Squamous Cell Carcinoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (49)
Prostate (50) (50) (50) (50)
Testes (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (49) (49)
Femoral, Hemangioma 1 (2%)
Lymph Node (49) (49) (45) (46)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%) 1 (2%)
Axillary, Deep Cervical, Mediastinal,
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Axillary, Mediastinal, Squamous Cell
Carcinoma, Metastatic, Skin 1 (2%)
Page 10
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Inguinal, Mediastinal, Squamous Cell
Carcinoma, Metastatic, Skin 1 (2%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic 1 (2%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%) 1 (2%) 1 (2%)
Lymph Node, Mandibular (48) (46) (43) (44)
Squamous Cell Carcinoma, Metastatic, Skin 2 (5%) 3 (7%)
Axillary, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Deep Cervical, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (5) (8) (13) (9)
Spleen (49) (50) (50) (50)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Keratoacanthoma 1 (2%)
Squamous Cell Carcinoma 1 (2%) 2 (4%) 3 (6%)
Squamous Cell Carcinoma, Multiple 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Back, Squamous Cell Carcinoma 4 (8%)
Scapula, Basal Cell Carcinoma 1 (2%)
Scapula, Basosquamous Tumor Malignant 2 (4%) 3 (6%)
Scapula, Squamous Cell Carcinoma 10 (20%) 27 (54%) 37 (74%)
Scapula, Squamous Cell Carcinoma, Multiple 2 (4%) 12 (24%) 5 (10%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1)
Diaphragm, Squamous Cell Carcinoma,
Metastatic, Skin 1 (100%)
Hindlimb, Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 7 (14%) 8 (16%) 8 (16%) 2 (4%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Basosquamous Tumor Malignant, Metastatic,
Skin 3 (6%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%)
Squamous Cell Carcinoma, Metastatic, Skin 2 (4%) 16 (32%) 20 (40%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (39) (42) (48) (42)
Adenoma 3 (8%) 6 (14%) 3 (6%) 4 (10%)
Carcinoma 1 (2%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Basosquamous Tumor Malignant, Metastatic,
Skin 2 (4%)
Squamous Cell Carcinoma, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 2 (4%) 3 (6%) 5 (10%)
Urinary Bladder (50) (48) (49) (48)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 2 (4%)
Lymphoma Malignant Mixed 2 (4%) 4 (8%)
Lymphoma Malignant Undifferentiated Cell 1 (2%) 1 (2%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05044-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 19:35:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 40 42 47
Total Primary Neoplasms 62 73 84 64
Total Animals with Benign Neoplasms 31 26 23 7
Total Benign Neoplasms 43 37 31 9
Total Animals with Malignant Neoplasms 16 26 40 47
Total Malignant Neoplasms 19 36 53 55
Total Animals with Metastatic Neoplasms 2 2 17 26
Total Metastatic Neoplasm 2 6 31 52
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 82292-82292/82292
--multipart-boundary--